December 29, 2022 7:40am
Final two (2) days as recession fears weigh on investor sentiment post a losing session, week, month and year
Pre-open Indication: 1 Positive and 1 Negative Indications
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
the 8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.26% or (+85 points), S&P futures are UP +0.45% or (+17 point) and NASDAQ futures are UP +0.63% or (+67 points) early in the pre-open – so far,
Stock futures rose slightly on Thursday a.m.,
European markets choppy as caution abounds to end the year,
Asia-Pacific markets traded lower.
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes fell on Wednesday as traders looked to the end of a losing year and prepared for 2023.
The Dow closed DOWN -365.85 points (-1.10%), the S&P closed DOWN -46.03 points (-1.20%) while the Nasdaq closed DOWN -139.94 points (-1.35%.
Economic Data Docket: weekly jobless claims before the bell. Economists are forecasting initial jobless claims to total 223,000 for the week ended Dec. 24, a rise from 216,000 during the previous period.
Wednesday’s (9/28) … RegMed Investors’ (RMi) closing bell: “sector expectation defined. Try speculation and exploitation by electronic trading.” … https://www.regmedinvestors.com/articles/12762
Ebb and flow:
Q4 – December – 1 holiday, 13 negative and 6 positive closes
· November -1 holiday, 14 negative and 8 positive closes
· October -1 neutral, 11 positive and 9 negative closes
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Take a turn at the dice throw:
CRISPR Therapeutics (CRSP) closed down -$1.82 to $39.19 after Tuesday’s -$3.08 with a positive +$0.19 or +0.46% pre-open indication,
Verve Therapeutics (VERV) closed up +$0.16 to $18.01 after Tuesday’s -$0.36 with a negative -$0.41 or -2.28% pre-open indication,
The BOTTOM LINE: I try to keep it simple and short!
If you've had a bad year, you're not going to make it up in the final two trading days of 2022 with the market struggling. Learn from your mistakes and prepare for the next sustained market rally in 2023. <IBD>
There's nothing wrong with taking no new positions, or even being entirely in cash.
Be prepared … just 2 trading days remain in 2022.
If you want to trade, sector exposure should be slim, limited only to positions that are working; investors might want to take partial profits or simply exit some trades with a gain.
I’d be calculating selling for tax purposes amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.
Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.